Jubilant Ingrevia Ltd Q4 FY26 Results Analysis: PAT Jumps 16.7%, Specialty Margin Expands 310 bps

Jubilant Ingrevia Ltd's Q4 FY26 numbers came in mixed, with revenue of Rs. 1,178.65 Cr (+12.10% YoY) and PAT growth of +16.72% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

JUBLINGREA delivered a strong Q4 with 12.1% revenue and 16.7% PAT growth, along with 310 bps margin expansion in specialty chemicals and a turnaround in the chemical intermediates segment. However, full-year results lagged management's aspirational targets: revenue grew only 5%, EBITDA growth was below 20% CAGR, and capex was 48% below guidance. The financial strength — evidenced by 1.89x cash conversion and 58% FCF growth — is positive, but the strategic targets appear aspirational without a significant growth acceleration.

Key Investment Insights

Key Positives

• Consolidated revenue grew 12.1% YoY to Rs.117,865 Lakhs in Q4 FY26.
• Consolidated PAT grew 16.7% YoY to Rs.8,644 Lakhs.
• Specialty Chemicals FY26 EBIT margin expanded 310 bps to 21.2%.
• Chemical Intermediates turned from a loss of Rs.191 Lakhs (Q4 FY25) to a profit of Rs.551 Lakhs (Q4 FY26).
• Cash from operations was 1.89x PAT at Rs.52,427 Lakhs.
• Free cash flow of Rs.22,491 Lakhs was up 58% YoY.
• Net debt declined 10.1% to Rs.591 Cr; debt-to-equity improved to 0.19x from 0.22x.

Risk Factors

• Revenue growth of 5.0% for full FY26 is below the aspirational 3x by FY'30 target.
• Nutrition & Health Solutions EBIT margin declined to 10.1% in FY26 from 11.7% in FY25, well below the 16-18% target.
• FY26 capex of Rs.310 Cr was 48% below the stated guidance of ~Rs.600 Cr.
• Chemical Intermediates FY26 EBIT margin compressed to 1.14% from 3.68% in FY25.
• Strong revenue growth in Q4 partly driven by Rs.2,301 Lakhs inventory build, which temporarily supported margins.
• Company's long-term aspirational targets (3x revenue, 4x EBITDA by FY'30) appear very difficult based on current 5% revenue and 9% EBITDA growth rates.